ZALTRAP 200 mg/8mL (Ziv-Aflibercept SOLUTION, CONCENTRATE) 200 mg/8mL

ZALTRAP 200 mg/8mL is a concentrated solution of ziv-aflibercept, used for specific medical treatments. This intravenous solution is designed for targeted therapy, offering a potent formulation in each 8mL vial.

Strength

200 mg/8mL

Pack Size

1 VIAL in 1 CARTON (0024-5841-01) / 8 mL in 1 VIAL

Manufacturer / TM Owner

sanofi-aventis U.S. LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ZALTRAP 200 mg/8mL is primarily used in the treatment of certain types of cancer. This medication works by targeting specific proteins involved in tumor growth and blood vessel formation. Patients often wonder, 'What is ziv-aflibercept used for?' It is typically administered intravenously as part of a broader treatment plan.

Side Effects

Common effects of ZALTRAP 200 mg/8mL may include fatigue, diarrhea, and high blood pressure. Some patients may experience appetite loss or nausea. These effects can vary depending on individual health conditions and treatment plans.

Precautions & Warnings

ZALTRAP 200 mg/8mL should be handled with care, as it is intended for professional medical use. It is important to follow proper storage and administration guidelines to ensure safety. Patients should discuss any pre-existing conditions with their healthcare provider before starting treatment.

Avoid Interactions

ZALTRAP 200 mg/8mL may interact with other medications, including those that affect blood pressure or the immune system. It is crucial to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements may also impact the effectiveness of this treatment.

References

Frequently Asked Questions

ZALTRAP 200 mg/8mL is used in the treatment of certain types of cancer, targeting proteins involved in tumor growth and blood vessel formation.

ZALTRAP 200 mg/8mL is administered intravenously by healthcare professionals as part of a treatment plan.

Common side effects may include fatigue, diarrhea, high blood pressure, appetite loss, and nausea.

ZALTRAP 200 mg/8mL may interact with other medications, so it is important to discuss all current medications with a healthcare provider.

ZALTRAP 200 mg/8mL should be stored according to the guidelines provided by the manufacturer to maintain its effectiveness.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.